Where Does Your CE Mark Take You? Multi-Country Registration Sequencing
For manufacturers who already hold one CE certificate and now need a multi-country registration plan: which regulators formally accelerate on a CE mark, which explicitly exclude it, and what sequence to file in — for a CE-only, CE+FDA, FDA-only, or NMPA+CE hand.
The direct answer
A CE mark is the world's most widely leveraged reference certificate for medical device registration — some form of formal recognition or evidentiary weight for it exists across Southeast Asia, the Gulf, South Asia, and parts of Latin America. But that leverage is not uniform, and in several major markets a CE mark formally counts for nothing in the fast lane: Brazil's regulatory-reliance pathway names exactly four reference agencies and explicitly excludes the EU; the Philippines' abridged route recognizes only ASEAN-member NRA approvals; Japan and the United States treat any foreign approval, CE included, as informal supporting evidence only, never a procedural shortcut. A multi-country CE-mark strategy means knowing both lists — where CE is a formal accelerant, where it is evidence-weight-only, and where it is structurally excluded — and sequencing filings so the CE-strong markets fund and de-risk the CE-blind ones.
Where CE works hardest
| Country | Type | Mechanism | What CE gets you |
|---|---|---|---|
| Australia | Formal | Overseas Conformity Assessment (OCA) Evidence: for Class IIb/III/AIMD, a NANDO-listed Notified Body CE substitutes for TGA’s own independent technical assessment, leaving only administrative conformity checking | CE sits at the identical, highest OCA tier as US FDA 510(k)/De Novo/PMA. NMPA is not a recognized OCA evidence type at all. |
| Singapore | Formal | HSA Reference Market system — Abridged (Class B/C/D, targets 100/160/220 working days), Immediate/Expedited (Class B same-day to 40 working days) | CE qualifies only if issued via direct EU Notified Body review (not MRA-based); self-declared Class I CE does not qualify. One of exactly 5 named agencies alongside US FDA, TGA, PMDA, and Health Canada. |
| Saudi Arabia | Formal | SFDA Abridged Review — Class C toward 6–12 months (vs. 12–24 Full), Class D toward 9–18 months (vs. 18–36+ Full) | CE (via an EU Notified Body) is one of 5 named reference agencies at formally equal standing with US FDA, TGA, PMDA, and Health Canada. |
| Malaysia | Formal | Formal CE recognition inside the standard conformity-assessment process — simplified pathway for Class A/B, materially fewer deficiency queries for Class C/D | MDR-issued CE is preferred over legacy MDD. The separate Verification Route (MDA/GD/0070) only names Singapore HSA and Thailand TFDA prior approval — CE alone does not enter that specific track. |
| Thailand | Formal | Expedited Review — roughly halves standard review time and removes Specialist Review risk | ≥1 year of approval from an EU Notified Body is one of 6 named qualifying references, alongside US FDA, TGA, Health Canada, Japan MHLW, and WHO Prequalification. |
| India | Formal, discretionary | CDSCO's Central Licensing Authority (CLA) may exempt or abbreviate the Indian clinical-investigation requirement, contingent on CLA being independently satisfied with the submitted data | The European Union is one of 6 named reference jurisdictions (with Australia, Canada, Japan, the UK, and the US), each requiring ≥2 years of clean market history. NMPA is not on this list. |
| Argentina | Formal, risk-class-limited | Decreto 892/25 sworn-declaration reliance — Clase I/II devices and non-cold-chain IVD Clase A/B are exempt from local testing and cleared via sworn-declaration notification | EU member states are named in Annex I (with Australia, EFTA, the US, Israel, Japan, and the UK). Clase III/IV devices are excluded entirely — CE there is only evidentiary in the standard review. |
| Vietnam | Evidence weight, near-prerequisite | No formal, procedurally separate fast track exists — reference-country evidence functions as a near-prerequisite for Type B/C/D, not an accelerant to a separate track | CE is accepted as overseas-registration proof under Decree 98/2021 with evidentiary weight equivalent to US FDA; PMA-grade clinical data can substitute for local clinical evidence on Type D devices specifically. |
| Indonesia | Evidence weight | No formal expedited or abbreviated route for CE-marked products — evidence reduces technical queries within the standard ASEAN CSDT review only | Must be Notified-Body-issued (self-declared does not qualify). For certain high-risk IVD categories, reference-country approval — CE among them — is a mandatory precondition, not an optional accelerator. |
| South Korea | Evidence weight only — a common point of confusion | MFDS's formal Abbreviated Review (약식심사) is FDA-specific only. CE is NOT eligible for it, even though it is often assumed to qualify alongside FDA. | CE is reused for IMDRF-STED-structured document drafting and supports (but does not itself satisfy) the overseas-marketing Certificate of Free Sale requirement. |
| Mexico⚑ | Excluded from the older mechanism; newer one unconfirmed | Acuerdo de Equivalencia (2010/2012) names exactly 3 authorities — US FDA, Health Canada, and Japan MHLW/PMDA — and the EU/CE is explicitly NOT on that list | The newer Vía Regulatoria Abreviada (effective Sept 1, 2025) is built on IMDRF Management Committee member authorities plus MDSAP-certified sites — broader on paper, but whether CE is enumerated within it is 【待核验】. |
Where CE does NOT unlock the fast lane
RDC 741/2022’s Regulatory Reliance ("via AREE") pathway names exactly 4 AREEs — US FDA, Health Canada, Australia TGA, and Japan MHLW/PMDA. The EU (CE, MDR or legacy MDD) is explicitly NOT on that list, and neither is China’s NMPA.
A CE-only holder should budget the full Class III/IV Registro track (18–30 / 36–60+ months). Two partial levers remain: obtaining any one of the 4 named AREEs (most practically US FDA) reclaims the ~30% ANVISA analysis-time reduction, and a separate MDSAP audit report — an audit-track credential, not a device-level one — can waive ANVISA’s own on-site BGMP inspection and extend BGMP validity from 2 to 4 years even while the device dossier itself proceeds through the standard review.
FDA Circular 2022-008’s formal abridged route (~30 business days) triggers only on prior approval from an ASEAN-member NRA. CE and US FDA alone do NOT trigger it — they remain reference evidence inside the standard CMDR review only.
Get Singapore HSA registration first (itself obtainable via HSA’s Abridged/Immediate/Expedited route using the CE file), then use that HSA registration — an ASEAN-member NRA approval — to unlock the Philippines’ ~30-business-day abridged clock. The CE/FDA file keeps strengthening the standard review in parallel.
No FDA/CE-keyed acceleration lever exists for anyone. Japan’s own formal accelerators (SAKIGAKE, target 6 months; Conditional Approval System) require Japan-first or Japan-simultaneous filing intent and genuine innovativeness — not simply holding a reference-market approval.
CE MDR technical files are reusable for document-preparation efficiency via the shared IMDRF STED structure, and CE is a supporting (not codified) factor in SAKIGAKE eligibility discussions — but PMDA can still request supplementary Japanese-population bridging data even with the file in hand. There is no structural shortcut to substitute for it.
No FDA/CE-keyed reliance or mutual-recognition mechanism exists. Every application completes the full statutory review regardless of foreign approval.
Restructure the CE technical file as clinical-evaluation source material, and pursue predicate/equivalent-device comparison (同品种比对) using overseas marketing and clinical data, or check eligibility against the category-based (not certificate-triggered) clinical-evaluation exemption catalogue. A clean overseas marketing history of ≥5 years supports exemption arguments, but Class III devices still need local clinical evidence absent a specific exemption.
FDA does not treat any foreign approval, including CE, as a reference market, and has no official channel for "simplified approval based on CE."
CE technical documentation can be reused for 510(k) substantial-equivalence argumentation or as part of a PMA clinical-evidence package — document/data reuse only, and must be independently reframed to FDA’s own substantial-equivalence or benefit-risk framework, using US-specific standards conformance (ISO/ANSI/ASTM), not EU-harmonized standards alone.
Recommended filing sequence, by certificate combination
① CE-only (typical European or Chinese exporter with a single CE certificate)
The most common starting hand for both European and Chinese medical device manufacturers: one MDR (or legacy MDD) CE certificate, no FDA or NMPA filing yet.
Sequence the CE-strong, fast markets first — including Singapore, whose resulting HSA registration becomes reference evidence for later filings — then the evidence-weight markets, and budget the CE-blind markets last as full, ground-up reviews or route them through a workaround.
Each names CE at formal, named-agency standing — TGA’s OCA Evidence, HSA’s Reference Market Abridged/Immediate/Expedited, SFDA’s Abridged Review, and Malaysia’s CE-recognition pathway — with materially compressed timelines. Singapore is worth sequencing early regardless of market priority, since the resulting HSA registration compounds forward into the Philippines and Malaysia’s Verification Route.
CE reduces deficiency-notice rounds and, in Vietnam and India, can substitute directly for local clinical evidence — but none of these grant a separately timed fast track the way Wave 1 does. Argentina is class-limited (Clase I/II only); larger, slower markets belong here rather than first.
File the Philippines using the Wave-1 Singapore HSA registration as the unlock, not CE directly. Budget Brazil, Japan, China, and the US as full, ground-up reviews where CE only reduces document-preparation effort — sequence these last so the earlier waves fund the longer cycles and any CE-blind-market workaround (an MDSAP audit, an FDA filing) can be planned rather than rushed.
② CE + FDA — near-universal coverage
A manufacturer holding both an EU CE certificate and a US FDA 510(k)/De Novo/PMA clearance.
Adding FDA to a CE-only hand does not change Wave 1 or Wave 2 — both already qualify on CE alone — but it unlocks two of the five Wave-3 markets outright and adds a formal mechanism CE never had access to.
FDA is one of Brazil's 4 named AREEs, so Brazil moves out of Wave 3 into Wave 1 behind an FDA filing. FDA is one of exactly 3 authorities on Mexico's original Acuerdo de Equivalencia (CE is not), so Mexico's exclusion resolves. And South Korea's Abbreviated Review (약식심사) is FDA-specific — CE alone never qualifies for it, but FDA does, moving Korea from evidence-weight-only into a formal, named track.
Neither FDA nor CE creates a formal shortcut in Japan (SAKIGAKE requires Japan-first filing intent, not a reference approval) or China (no reliance mechanism keyed to any foreign authority). Both remain full, ground-up reviews regardless of which reference certificates are in hand.
③ FDA-only
A US-based or US-first manufacturer with an FDA 510(k), De Novo, or PMA clearance and no CE certificate yet.
FDA alone reaches nearly every Wave-1 and Wave-2 market from the CE-only sequence — it is named alongside CE in Singapore, Saudi Arabia, Malaysia, Thailand, India, and Argentina, and separately in Vietnam under Decree 98/2021 — plus it independently unlocks Brazil, Mexico, and South Korea the same way it does for the CE+FDA hand. What FDA-only does not buy is EU/UK market access itself, which is moot unless that market is part of the plan; add a CE certificate later purely to open the EU/UK/EEA, not to accelerate elsewhere.
US FDA appears on the named-agency list for every one of these mechanisms, at the same or better standing than CE.
Brazil’s AREE list, Mexico’s original Acuerdo de Equivalencia, and Korea’s Abbreviated Review are all FDA-inclusive and CE-exclusive — an FDA-only hand reaches these markets that a CE-only hand cannot.
④ NMPA + CE (typical Chinese manufacturer hand)
A Chinese manufacturer with NMPA clearance in the home market and one CE certificate for the EU — the most common export-ready hand for China-based medical device companies.
NMPA is recognized as a reference approval almost nowhere on this page: it is explicitly excluded from Singapore’s 5 named agencies, Saudi Arabia’s 5, Brazil’s 4, Mexico’s 3, Argentina’s 7 jurisdictions, India’s 6, and Australia’s OCA tiers, and is treated with added scrutiny — not credit — in Taiwan on political grounds. CE therefore carries essentially the entire international-reliance load for this hand, and the recommended sequence is identical to the CE-only playbook. The one structural difference is China itself: this hand already has full China market access, skipping the CE-blind China problem entirely, and an established China manufacturing/commercial base can support faster onward evidence generation — additional predicate data, clinical experience, and supply-chain scale — for the markets in Wave 2 and Wave 3 that still call for local evidence.
See the CE-only sequence above — CE is doing the same job here that it does for a European CE-only holder, since NMPA adds essentially no cross-border reference value.
China itself moves from Wave 3’s "full, ground-up review" problem to "already solved" — the only market on this page where NMPA outperforms CE outright.
Reference value chains, recapped
Singapore HSA is the most reusable downstream credential in a CE-first sequence
A Singapore HSA registration — itself obtained via Abridged/Immediate/Expedited using the CE file — is the only approval type that unlocks the Philippines’ formal ~30-business-day abridged clock, and it is a named reference authority inside Malaysia’s Verification Route. Vietnamese and Thai reviewers also weigh an existing HSA approval as supporting evidence. This is why Singapore sits in Wave 1 of every hand above regardless of market priority.
MDSAP is not CE — it is a separate, site-level audit credential that compounds independently
MDSAP audit reports work through a structurally different lever than device-level CE reliance: Brazil's ANVISA can waive its own on-site BGMP inspection on an MDSAP report and extend BGMP validity from 2 to 4 years; Japan's PMDA accepts MDSAP reports as QMS Ordinance No. 169 conformity evidence; Canada makes MDSAP mandatory for Class II–IV, where CE approval does not substitute for it; and Mexico's 2025 Vía Regulatoria Abreviada names MDSAP-certified sites as its GMP-evidence basis. A manufacturer whose only formal reliance evidence is a CE certificate should not assume MDSAP coverage comes with it — MDSAP requires its own separate site audit, and it is the one lever that still helps in Brazil and Mexico even where CE is structurally excluded from the device-dossier reliance list.
Pitfalls
- MDR vs. legacy MDD CE distinctions get treated as interchangeable when they are not: Malaysia’s formal CE-recognition pathway names MDR-issued CE as preferred over legacy MDD, and other markets weigh the two differently. Check the relevant country page before assuming a legacy MDD certificate carries the same leverage as an MDR one, especially as the EU’s own MDR transitional deadlines (Class III/IIb by December 2027, lower-risk by December 2028) approach.
- CE scope and issuance-route mismatches quietly disqualify a certificate from leverage it looks like it should have: Singapore requires direct Notified Body review (not MRA-based) and rejects self-declared Class I CE outright; Indonesia and Australia impose the same Notified-Body-issued requirement. A self-declared Class I CE Declaration of Conformity does not unlock any formal or evidence-weight leverage documented on this page — verify the issuance route and device scope against the CE certificate itself, not just its existence.
- Automatic classification mapping does not occur almost anywhere on this page — not in Singapore (HSA applies its own GN-13/GN-14 rules), not in Malaysia, Saudi Arabia, or Australia (ARTG scope must fully match OCA evidence scope). A CE Class IIa device is not automatically the local-equivalent class; confirm classification independently in each market before assuming the CE class carries over.
- None of the routes on this page — formal or evidence-weight — waive the local certificate-holder or Authorized Representative requirement, local-language labelling, or post-market obligations. A formal fast lane compresses the regulator’s own technical-review time only; the surrounding local compliance stack (holder structure, labelling, vigilance reporting) is unaffected by which reference certificates are in hand.
Go deeper on any single market
This page is the CE-specific cut of a larger cross-country leverage matrix. Open the full matrix for every reference certificate, or any country report for the complete mechanism, timeline, and dossier detail.